Imatinib impairs the proliferation and function of CD4+CD25 + regulatory T cells in a dose-dependent manner

International Journal of Oncology

Volumn 31, Issue 5, 2007, Pages 1133-1139

  Chen, Jinfei ^a,b   Schmitt, Anita ^a   Giannopoulos, Krzysztof ^a,c   Chen, Baoan ^b   Rojewski, Markus ^a   Döhner, Hartmut ^a   Bunjes, Donald ^a   Schmitt, Michael ^a  

^a UNIVERSITY OF ULM   (Germany)

^b MEDICAL SCHOOL OF SOUTHEAST UNIVERSITY   (China)

^c MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

CD4+CD25+ regulatory T cells; Imatinib; Proliferation

Indexed keywords

ANTINEOPLASTIC AGENT; CD69 ANTIGEN; CYTOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; CYTOTOXIC T-LYMPHOCYTE ANTIGEN 4; DIFFERENTIATION ANTIGEN; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN; IMATINIB; LEUKOCYTE ANTIGEN; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE; T LYMPHOCYTE ANTIGEN; UNCLASSIFIED DRUG;

ARTICLE; BIOSYNTHESIS; CELL CULTURE; DOSE RESPONSE; DRUG EFFECT; HUMAN; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; REGULATORY T LYMPHOCYTE;

ANTIGENS, CD; ANTIGENS, DIFFERENTIATION; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; ANTINEOPLASTIC AGENTS; CELLS, CULTURED; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; LYMPHOCYTE ACTIVATION; PIPERAZINES; PYRIMIDINES; T-LYMPHOCYTES, REGULATORY;

EID: 38449083810     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Druker BJ, Tamura S, Buchdunger E, et al: Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2: 561-566, 1996.
2. Druker BJ, Talpaz M, Resta DJ, et al: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344: 1031-1037, 2001.
3. Deininger MW, Goldman JM, Lydon N and Melo JV: The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood 90: 3691-3698, 1997.
4. Appel S, Balabanov S, Brummendorf TH and Brossart P: Effects of imatinib on normal haematopoiesis and immune activation. Stem Cells 23: 1082-1088, 2005.
5. Appel S, Rupf A, Weck MM, et al: Effects of imatinib on monocyte-derived dendritic cells are mediated by inhibition of nuclear factor-kappa B and Akt signaling pathways. Clin Cancer Res 11: 1928-1940, 2005.
6. + T lymphocytes specifically directed against the leukemia-associated antigen RHAMM/CD168 in vitro. Cancer Immunol Immunother 56: 849-861, 2007.
7. Gao H, Lee BN, Talpaz M, et al: Imatinib mesylate suppresses cytokine synthesis by activated CD4 T cells of patients with chronic myelogenous leukemia. Leukemia 19: 1905-1911, 2005.
8. Chen ML, Pittet MJ, Gorelik L, et al: Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-β signals in vivo. Proc Natl Acad Sci USA 102: 419-424, 2005.
9. + regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med 9: 1144-1150, 2003.
10. Zou W: Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 6: 295-307, 2006.
11. Rezvani K, Mielke S, Ahmadzadeh M, et al: High donor FOXP3-positive regulatory T-cell (Treg) content is associated with a low risk of GVHD following HLA-matched allogeneic SCT. Blood 108: 1291-1297, 2006.
12. + T cells to allow an effective graft-vs.-leukemia response. Biol Blood Marrow Transplant 9: 243-256, 2003.
13. + regulatory T cells favor immune reconstitution and control graft-versus-host disease while maintaining graft-versus-leukemia. J Clin Invest 112: 1688-1696, 2003.
14. Savani BN, Montero A, Kurlander R, Childs R, Hensel N and Barrett AJ: Imatinib synergizes with donor lymphocyte infusions to achieve rapid molecular remission of CML relapsing after allogeneic stem cell transplantation. Bone Marrow Transplant 36: 1009-1015, 2005.
15. Weisser M, Tischer J, Schnittger S, Schoch C, Ledderose G and Kolb HJ: A comparison of donor lymphocyte infusions or imatinib mesylate for patients with chronic myelogenous leukemia who have relapsed after allogeneic stem cell transplantation. Haematologica 9: 663-666, 2005.
16. Chunduri S, Dobogai LC, Bruno A, Kadkol S and Rondelli D: Does post-transplant treatment with imatinib mesylate inhibit graft-versus-leukemia? Leukemia 19: 456-457, 2005.
17. Schmitt M, Schmitt A, Reinhardt P, et al: Opsonization with a trifunctional bispecific (αCD3 x αEpCAM) antibody results in efficient lysis in vitro and in vivo of EpCAM positive tumor cells by cytotoxic T lymphocytes. Int J Oncol 25: 841-848, 2004.
18. + T cells of HLA-A2-positive patients with acute myeloid leukemia. Blood 106: 938-945, 2005.
19. +CD25 high regulatory cells in human peripheral blood. J Immunol 167: 1245-1253, 2001.
20. Ormandy LA, Hillemann T, Wedemeyer H, Manns MP, Greten TF and Korangy F: Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res 65: 2457-2464, 2005.
21. Moore KW, De Waal Malefyt R, Coffman RL and O'Garra A: Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 19: 683-765, 2001.
22. Ding Y, Chen D, Tarcsafalvi A, Su R, Qin L and Bromberg JS: Suppressor of cytokine signaling 1 inhibits IL-10-mediated immune responses. J Immunol 170: 1383, 2003.
23. + regulatory T cells. J Exp Med 201: 1061-1067, 2005.
24. + cells with CD3 and CD46 induces a T-regulatory cell 1 phenotype. Nature 421: 388-392, 2003.
25. Grossman WJ, Verbsky JW, Tollefsen BL, Kemper C, Atkinson JP and Ley TJ: Differential expression of granzymes A and B in human cytotoxic lymphocyte subsets and T regulatory cells. Blood 104: 2840-2848, 2004.
26. + regulatory T cells through GITR breaks immunological self-tolerance. Nat Immunol 3: 135-142, 2002.
27. Ramsdell F and Ziegler SF: Transcription factors in autoimmunity. Curr Opin Immunol 15: 718-724, 2003.
28. + regulatory T cells. Int Immunol 16: 1643-1656, 2004.
29. + T regulatory cells. Nat Immunol 4: 337-342, 2003.
30. Hori S, Nomura T and Sakaguchi S: Control of regulatory T cell development by the transcription factor Foxp3. Science 299: 1057-1061, 2003.
31. + regulatory T cells. Nat Immunol l4: 330-336, 2003.
32. Peng B, Hayes M, Resta D, et al: Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. J Clin Oncol 22: 935-942, 2004.
33. Seggewiss R, Lore K, Greiner E, et al: Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner. Blood 105: 2473-2479, 2005.